Thyroid disorders in 2 cases of acute myeloid leukaemia following treatment with recombinant interleukin-2 infusion.
Two AML patients treated with recombinant interleukin-2 infusion without LAK cells developed thyroid complications within 2 months following the treatment. One patient was clinically and biochemically hypothyroid but was negative for thyroid autoantibodies while the other patient developed thyroid microsomal autoantibody but remained euthyroid. These 2 cases represent the two ends of the spectrum of thyroid complications following interleukin-2 therapy. Such complications are not uncommon but are poorly documented. We suggest that patients receiving cytokine therapy should be followed up closely for any autoimmune complications.
Lim
S H
SH
Department of Haematology, University College Hospital, London, UK.
Callaghan
T
T
Goldstone
A H
AH
D000328:Adult; D001327:Autoimmune Diseases / Q000139:chemically induced; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000139:chemically induced*
D007376:Interleukin-2; D011994:Recombinant Proteins